FDA approves Myoview for use with stress agents:
This article was originally published in Clinica
Amersham Health has received US FDA approval for the additional use of its Myoview radiopharmaceutical with pharmacological stress agents, which are used in the diagnosis of coronary artery diseases in patients unable to exercise physically. The product was introduced in the US in 1996 where it has captured over 35% of the technetium cardiac market says the UK-based firm.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.